blood test
BiologicalResidue of blood further to NFS.
NCT Number: NCT01995448
Septic shock is still a major cause of death in ICU. Sepsis diagnosis is linked with many clinical, hemodynamic and biological criteria which have a low sensitivity and specificity if they are considered separately. The extensive experimental data which have been published contrast with the hematological data collected by the physician at patient's bedside especially regarding neutrophils and platelets levels. When there is no obvious clinical sign, a biological tool reflecting the patient's immune status could be useful to understand the physiopathology of Sepsis and to predict the progression of the disease in the patient. On the long-term it could also help to define management strategies.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
CHU Bordeaux - Service Réanimation Médicale, Bordeaux, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Residue of blood further to NFS.
Time frame: 28 days
Expression of CD10 on granulocytes.
Time frame: 48 hours
Time frame: 28 days
Expression of CD16 on granulocytes and on monocytes.
Time frame: 28 days
Expression of CD24 on granulocytes.
Time frame: 28 days
Expression of CD64 on granulocytes.
Time frame: 28 days
Expression of CD14 on monocytes.
Time frame: 28 days
Expression of CD3 on T lymphocytes.
University Hospital, Limoges
Other
Prognostic Interest of Leucocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry During the Acute Phase of Sepsis
Acronym: SEPTIFLUX2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06809868
Coinfection, Infections
San Francisco, California, United States
View Trial Details